Radiopharm Theranostics : RAD Dual Action Antibody Investor Deck

Further expanding one of the deepest pipeline in the sector with

DUAL ACTION LRRC15-TARGETING MONOCLONAL ANTIBODY FROM UCLA

April 2022

Riccardo Canevari

CEO, Radiopharm Theranostics Ltd

INVESTMENT HIGHLIGHTS

LRRC15-targeting antibody "DUNP19" holds the potential of first in class therapy in different solid tumor types.

THE ROAD AHEAD

mAb manufacturing

Less than 6 months for cGMP

Phase 1 DUNP19

12month to be started

Lead indication: Osteosarcoma (OS)

high unmet need, orphan status, fast approval & limited competition

2

THE TECHNOLOGY & MoA

LRCC15 expression is produced by cancer cells

AND the surrounding tumour micro-environment, but not by healthy normal tissues.

The LRRC15-targeted radiopharmaceutical therapy has unique "dual action," i.e. targeting both the tumour cells and the surrounding environment (stroma).

The radionuclide carrying LRRC15-targeting antibody "DUNP19" holds the potential of first in class therapy in a range of solid tumour types.

Osteosarcoma has a high unmet medical need and impacts young adult population most commonly, which is the first disease against which this antibody will be tested.

INVENTOR & INSTITUTION

Dr. David Ulmert, MD, PhD

Dr Ulmert obtained his degrees from Lund University, Sweden. He is currently lab head, faculty member and director of the preclinical theranostics program at the department of molecular and medical, UCLA.

Prior to joining UCLA, Dr. Ulmert spent 9 years at MSKCC where he served as the technical director of Ludwig Center for Cancer Immunotherapy between 2014-2018. In addition, Dr. Ulmert holds a position as lab head at the department of oncology at Lund University, Sweden.

His research focus on development of multimodal vehicles targeting biomarkers related to progression and treatment resistance in oncological diseases. Several of the inventions developed by his teams are currently being evaluated in clinical trails.

Dr. Ulmert has co-founded biotech start-ups (Diaprost and Pharma15) that have successfully out-licensed several radiotheranostic and immunotherapeutic compounds. He serves as a scientific advisor to several pharmaceutical companies, including RAD.

• ▪ The University of California, Los Angeles (UCLA)

  • - UCLA is frequently ranked among the best universities in the United States by major college and university rankings.

  • - As of October 2021, 27 Nobel laureates, five Turing Award winners, two Chief Scientists of the U.S. Air Force and one Fields Medalist have been affiliated with UCLA as faculty, researchers or alumni.

  • - Among the current faculty members, 55 have been elected to the National Academy of Sciences, 32 to the National Academy of Engineering, 41 to the National Academy of Medicine and 156 to the American Academy of Arts and Sciences.

-

The university was elected to the Association of American Universities in 1974.

PRECLINICAL DATA - THE TARGET:

Leucin Rich Repeat Containing Protein 15 (LRRC15)